114 related articles for article (PubMed ID: 6543405)
1. In vitro fibrinolytic activity of recombinant tissue-type plasminogen activator in the plasma of various primate species.
Lijnen HR; Marafino BJ; Collen D
Thromb Haemost; 1984 Dec; 52(3):308-10. PubMed ID: 6543405
[TBL] [Abstract][Full Text] [Related]
2. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
Lijnen HR; De Wreede K; Demarsin E; Collen D
Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
4. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
Korninger C; Collen D
Thromb Haemost; 1981 Aug; 46(2):561-5. PubMed ID: 6795744
[TBL] [Abstract][Full Text] [Related]
5. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
[TBL] [Abstract][Full Text] [Related]
6. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J
J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693
[TBL] [Abstract][Full Text] [Related]
7. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
Zamarron C; Lijnen HR; Van Hoef B; Collen D
Thromb Haemost; 1984 Aug; 52(1):19-23. PubMed ID: 6495259
[TBL] [Abstract][Full Text] [Related]
8. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activators and inhibitors are transcribed during early macaque implantation.
Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD
Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823
[TBL] [Abstract][Full Text] [Related]
11. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
12. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
13. Divergent expression of cellular prion protein on blood cells of human and nonhuman primates.
Holada K; Simak J; Brown P; Vostal JG
Transfusion; 2007 Dec; 47(12):2223-32. PubMed ID: 17714417
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning of the cDNA encoding the carboxy-terminal domain of chimpanzee apolipoprotein(a): an Asp57 --> Asn mutation in kringle IV-10 is associated with poor fibrin binding.
Chenivesse X; Huby T; Wickins J; Chapman J; Thillet J
Biochemistry; 1998 May; 37(20):7213-23. PubMed ID: 9585533
[TBL] [Abstract][Full Text] [Related]
15. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
16. Impaired fibrinolytic potential related to elevated alpha1-proteinase inhibitor levels in patients with pulmonary thromboembolism.
Gombás J; Kolev K; Tarján E; Machovich R
Ann Hematol; 2004 Dec; 83(12):759-63. PubMed ID: 15316758
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor.
Korninger C; Collen D
Thromb Haemost; 1981 Oct; 46(3):662-5. PubMed ID: 6171907
[TBL] [Abstract][Full Text] [Related]
18. In vitro effects of the acylated streptokinase-plasminogen activator complex BRL 33 575 incubated with normal human plasma.
Lämmle B; Noll G; Tran TH; Lohri A; Duckert F
Thromb Haemost; 1984 Jul; 51(3):403-5. PubMed ID: 6548585
[TBL] [Abstract][Full Text] [Related]
19. Changes in pericardial morphology and fibrinolytic activity during cardiopulmonary bypass.
Nkere UU; Whawell SA; Thompson EM; Thompson JN; Taylor KM
J Thorac Cardiovasc Surg; 1993 Aug; 106(2):339-45. PubMed ID: 8341074
[TBL] [Abstract][Full Text] [Related]
20. [Role of the initial level of plasminogen activator in changes in fibrinolysis].
Andreenko GV; Liutova LV; Karabasova MA; Podorol'skaia LV; Serebriakova TN
Fiziol Zh SSSR Im I M Sechenova; 1983 Mar; 69(3):380-5. PubMed ID: 6343132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]